Journal
JOURNAL OF MICROENCAPSULATION
Volume 31, Issue 5, Pages 501-507Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/02652048.2013.879932
Keywords
Celastrol; liposomes; prostate cancer
Funding
- Methodist Hospital Research Institute
- Ernest Cockrell Jr. Distinguished Endowed Chair
- US Department of Defense [W81XWH-09-1-0212]
- National Institute of Health [U54CA143837, U54CA151668]
- Nylands nation Finland
- Department of Defense [W81XWH-12-1-0414]
- State of Texas CPRIT grant [RP121071]
- NATIONAL CANCER INSTITUTE [U54CA143837, U54CA151668] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Context: Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilising agents. Materials and methods: Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells. Results: Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available